☍ On December 23, 2015, the founder team established Rendong Medical
☍ The 1600m² medical inspection center established in accordance with international standards was completed and put into use
☍ The underlying R&D + technology platform construction, the original liquid biopsy technology: S-Type™ database construction technology and UMT™ technology
☍ Launched a series of products for individualized diagnosis and treatment of tumors, covering the whole cycle before, during and after diagnosis and treatment
☍ The 10,000-person Tumor Immunity Ark Project was officially launched in Beijing
☍ The first ctDNA Panel for the efficacy of tumor immunotherapy was launched
☍ 19 independently developed software obtained the computer software copyright of the National Copyright Administration
☍ The laboratory has passed the inter-laboratory quality assessment of the Ministry of Health Clinical Inspection Center
☍ Scientific research cooperation agreements on precision immunotherapy for head and neck tumors and liver cancer have been signed one after another
☍ Received 75 million A round strategic investment from well-known institutions
☍ Prostate cancer precision diagnosis and treatment products were launched
☍ Prostate cancer summit forum and academic salon were held to promote the road of prostate cancer precision diagnosis and treatment
☍ National Lung Cancer Alliance multi-center project was launched
☍ Appeared at CSCO, the latest scientific research results were released
☍ Cooperation with well-known domestic pharmaceutical companies such as Hengrui Pharmaceutical and Yuheng Pharmaceutical
☍ Won the 2018 Digital Medical Excellent Cooperation Case Most Attention Award and Excellent Cooperation Case Award
☍ Settled in Zhangjiang Cell Industrial Park, the 3000㎡ medical laboratory research center was completed and put into use
☍ Renal cancer, urothelial cancer, hereditary calculi products were released, and the construction of the extra-urology product system was completed
☍ The European leading product Prostatype®was introduced to create extra-urology diagnosis Closed-loop
☍ Exclusive participation in the review meeting of the 2019 Prostate Cancer Diagnosis and Treatment Guidelines, precision diagnosis and treatment written into the guidelines
☍ Join hands with Johns Hopkins University to hold the first Sino-US Symposium on Precision Medicine for Urological Tumors
☍ Jointly sponsored by Wu Jieping Medical Foundation "Benevolence- The "Precision Decision-making in Urology" special fund was launched
☍ The largest cohort database of colorectal cancer liver metastasis in China was established
☍ The Lung Cancer Ark Project was fully launched, and the first article was accepted
☍ Cooperated with Zero Krypton Technology to explore real-world data research
☍ Won the recognition of high-tech enterprises, helping National Technological Innovation
☍ Won the 2019 Sullivan China New Economy-Excellent Science and Technology Innovation Award
☍ Cooperated with AstraZeneca to develop the first prostate cancer companion diagnostic product in China Pioneer and Huimei jointly build a patient-centered, integrated tumor precision treatment platform
☍ Start drug marketing cooperation with Sanofi, InnoCare and BeiGene
☍ Start commercialization of Prostatype® in China with Sweden’s Prostatype Genomics Progress
☍ Launched "Renyi Online-Prostate Cancer Patient Care Project" to help implement hierarchical diagnosis and treatment
☍ Rendong Medical Research Institute was established, dedicated to medical scientific research and product technology innovation
☍ Self-developed and built one-stop multi-dimensional data integration and interaction platform - Release of Haiji System
☍ Results of Immune Ark Program - The first comprehensive database of tumor immunotherapy IO-Portal launched Laboratory certificate, Super-MSI bottom technology construction completed
☍ Suzhou 4000 square meters base started planning and construction, IVD development plan officially launched
☍ Completed 100 million yuan B round of financing to accelerate the integration of precision diagnosis and treatment
☍ Passed the CAP authoritative certification of the international authoritative clinical laboratory quality certification system
☍ Nature sub-journal released the latest research results in the field of colorectal cancer early screening
☍ Cooperated with Renji Hospital to map late-stage metastasis in China Gene mutation map of blood samples from prostate cancer patients
☍ Cooperated with Peking University Cancer Hospital to release the results of China's largest colorectal cancer liver metastasis cohort Hengbio cooperates with precision immunotherapy marker exploration and research to a successful conclusion
☍ Deploy tumor early screening product line, and introduce drugs and medical device products China Urinary Genetics and Rare Disease Alliance was established to jointly promote the prevention, diagnosis and treatment of rare diseases Award
☍ Published 25 SCI articles in the past two years, with a cumulative impact factor of nearly 200 points
400-696-6908Contact Information
info@gloriousmed.comEmail
No. 11, Lane 100, Banxia Road, Pudong New Area, ShanghaiCompany address
400-696-6908Contact Information
info@gloriousmed.comEmail
No. 11, Lane 100, Banxia Road, Pudong New Area, ShanghaiCompany address
Follow us to learn moreWeChat public account
